<DOC>
	<DOC>NCT01431053</DOC>
	<brief_summary>This is a phase II study to assess efficacy/safety of Exemestane with or without Aspirin as the adjuvant treatment in postmenopausal breast cancer patients.</brief_summary>
	<brief_title>Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>Breast cancer after surgery postmenopausal contraindication of aspirin</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>exemestane</keyword>
	<keyword>aspirin</keyword>
	<keyword>quality of life</keyword>
</DOC>